The potential risk of infections during (prolonged) rituximab therapy in rheumatoid arthritis

Author： Brinkman Ithamar Heber   Laar Mart AFJ van de   Jansen Tim L   van Roon Eric N  

Publisher： Informa Healthcare

ISSN： 1474-0338

Source： Expert Opinion on Drug Safety, Vol.10, Iss.5, 2011-09, pp. : 715-726

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Rituximab therapy effective for rheumatoid arthritis?

By  

Inpharma, Vol. 1, Iss. 1443, 2004-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite

Newer Immunosuppressive Drugs: Their Potential Role in Rheumatoid Arthritis Therapy

By Drosos A.A.  

Drugs, Vol. 62, Iss. 6, 2002-01 ,pp. : 891-907

Adis International

Access to resources Recommend Favorite

Targeted therapy in rheumatoid arthritis

By Kller Marcus D  

Expert Opinion on Drug Discovery, Vol. 3, Iss. 3, 2008-03 ,pp. : 329-342

Informa Healthcare

Access to resources Recommend Favorite

Biologic Therapy in Rheumatoid Arthritis

By  

Current Topics in Medicinal Chemistry, Vol. 13, Iss. 6, 2013-03 ,pp. : 752-759

Bentham Science Publishers

Access to resources Recommend Favorite

Gene Therapy for Rheumatoid Arthritis

By  

Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Inflammatory and Anti-Allergy Agents), Vol. 6, Iss. 2, 2007-05 ,pp. : 109-120

Bentham Science Publishers

Access to resources Recommend Favorite